Mirum Pharmaceuticals posted a Phase 3 result for its chronic hepatitis delta program, reporting that the trial hit its primary endpoint. The readout advances Mirum’s effort to establish a differentiated option in a therapeutic area recently dominated by Gilead and now being contested by next entrants. For payers and clinicians, the key follow-on will be depth of response durability, safety/tolerability, and how the regimen fits alongside existing care pathways. Investors will also watch Mirum’s next steps toward regulatory filings and how endpoints translate into label positioning.